{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-008707","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.731507+00:00","generated_at":"2026-05-15T22:20:36.888509+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MIRA completes Phase 1 dosing of Ketamir-2; no serious AEs; plans Phase 2a in CIPN","bullets":["Completed Phase 1 study in 56 healthy volunteers; no serious adverse events or dose-limiting toxicities.","No clinically significant dissociative or psychotomimetic effects typically seen with ketamine observed.","Plans to submit Phase 2a proof-of-concept study to FDA in H1 2026 for chemotherapy-induced peripheral neuropathy (CIPN).","CIPN lacks FDA-approved therapies; Ketamir-2 is a selective oral NMDA receptor modulator."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-008707","json":"https://secwatch.observer/filing/0001493152-26-008707.json","markdown":"https://secwatch.observer/filing/0001493152-26-008707.md","text":"https://secwatch.observer/filing/0001493152-26-008707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226008707/0001493152-26-008707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226008707/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:20:36.888509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}